Gilead Sciences Stock Forecast, Price & News

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gilead Sciences stock.
View analyst ratings for Gilead Sciences or view top-rated stocks.

Wall Street analysts have given Gilead Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Gilead Sciences.

Gilead Sciences will be holding an earnings conference call on Thursday, July 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings data on Thursday, April, 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.06 by $0.02. The biopharmaceutical company earned $6.42 billion during the quarter, compared to analysts' expectations of $6.78 billion. Gilead Sciences had a trailing twelve-month return on equity of 51.91% and a net margin of 1.18%.
View Gilead Sciences' earnings history.

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GILD shares have decreased by 6.7% and is now trading at $68.75.
View which stocks have been most impacted by COVID-19.

Gilead Sciences announced a quarterly dividend on Thursday, April 29th. Investors of record on Tuesday, June 15th will be given a dividend of $0.71 per share on Tuesday, June 29th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.13%. The ex-dividend date is Monday, June 14th.
View Gilead Sciences' dividend history.

Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.11%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences does not yet have a strong track record of dividend growth. The dividend payout ratio of Gilead Sciences is 40.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.34% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

Gilead Sciences issued an update on its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share guidance of 6.750-7.450 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.170. The company issued revenue guidance of $21.70 billion-$22.10 billion, compared to the consensus revenue estimate of $24.78 billion.

20 Wall Street analysts have issued twelve-month price targets for Gilead Sciences' shares. Their forecasts range from $61.00 to $625.00. On average, they anticipate Gilead Sciences' stock price to reach $101.95 in the next year. This suggests a possible upside of 48.3% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of GILD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Confluence Investment Management LLC (0.10%), TCW Group Inc. (0.05%), Private Management Group Inc. (0.05%), State of Alaska Department of Revenue (0.04%), Manning & Napier Group LLC (0.04%) and Oregon Public Employees Retirement Fund (0.03%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including TCW Group Inc., Gofen & Glossberg LLC IL, Oregon Public Employees Retirement Fund, Focused Wealth Management Inc, First PREMIER Bank, Fulton Bank N.A., 6 Meridian, and Spirit of America Management Corp NY. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Johanna Mercier, Merdad Parsey, and Richard James Whitley.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.

GILD stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Brookstone Capital Management, IFM Investors Pty Ltd, Confluence Investment Management LLC, State of Alaska Department of Revenue, Cardinal Capital Management Inc., Vancity Investment Management Ltd, and WNY Asset Management LLC.
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $68.75.

Gilead Sciences has a market capitalization of $86.22 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $7.09 on an earnings per share basis.

Gilead Sciences employs 13,600 workers across the globe.

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences llac Ticaret Limited Sirketi, Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, Kite Pharma UK Ltd, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

Gilead Sciences was founded in 1987.

The official website for Gilead Sciences is www.gilead.com.

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 574-3000 or via email at [email protected]